Amnestic syndrome of the hippocampal type (ASHT) in Memory Clinics is a presentation common to Alzheimer’s disease (AD). However, ASHT can be found in other neurodegenerative disorders.
Objective:
To compare brain morphometry including hippocampal volumes between amnestic older adults with and without AD pathology and investigate their relationship with memory performance and cerebrospinal fluid (CSF) biomarkers.
Methods:
Brain morphometry of 92 consecutive patients (72.5±6.8 years old; 39% female) with Free and Cued Selective Recall Reminding Test (FCSRT) total recall < 40/48 was assessed with an automated algorithm and compared between AD and non-AD patients, as defined by CSF biomarkers.
Results:
AD and non-AD patients presented comparable brain morphology. Total recall was associated to hippocampal volume irrespectively from AD pathology.
Conclusions:
Brain morphometry, including hippocampal volumes, is similar between AD and non-AD older adults with ASHT evaluated in a Memory Clinic, underlying the importance of using molecular biomarkers for the diagnosis of AD.
SarazinM, BerrC, De RotrouJ, FabrigouleC, PasquierF, LegrainS, MichelB, PuelM, VolteauM, TouchonJ, VernyM, DuboisB (2007) Amnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study. Neurology69, 1859–1867.
4.
BertouxM, CassagnaudP, LebouvierT, LebertF, SarazinM, Le BerI, DuboisB, NeuroCEB Brain Bank, AuriacombeS, HannequinD, WallonD, CeccaldiM, MaurageC-A, DeramecourtV, PasquierF (2020) Does amnesia specifically predict Alzheimer’s pathology? A neuropathological study. Neurobiol Aging95, 123–130.
5.
LagardeJ, OlivieriP, ToniettoM, GervaisP, ComtatC, CailléF, BottlaenderM, SarazinM (2021) Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type. Transl Psychiatry11, 498.
6.
BaldaranovD, GarciaV, MillerG, DonohueMC, ShawLM, WeinerM, PetersenRC, AisenP, RamanR, RafiiMS (2023) Safety and tolerability of lumbar puncture for the evaluation of Alzheimer’s disease. Alzheimers Dement (Amst)15, e12431.
7.
JackCR, BarkhofF, BernsteinMA, CantillonM, ColePE, DecarliC, DuboisB, DuchesneS, FoxNC, FrisoniGB, HampelH, HillDLG, JohnsonK, ManginJ-F, ScheltensP, SchwarzAJ, SperlingR, SuhyJ, ThompsonPM, WeinerM, FosterNL (2011) Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement7, 474–485.e4.
8.
QuekY-E, FungYL, CheungMW-L, VogrinSJ, CollinsSJ, BowdenSC (2022) Agreement between automated and manual MRI volumetry in Alzheimer’s disease: A systematic review and meta-analysis. J Magn Reson Imaging JMRI56, 490–507.
DraganskiB, KherifF, DamianD, DemonetJ-F, Consortium for the M (2019) A nation-wide initiative for brain imaging and clinical phenotype data federation in Swiss university memory centres. Curr Opin Neurol32, 557.
11.
Clifford R. JackJ, BennettDA, BlennowK, CarrilloMC, DunnB, HaeberleinSB, HoltzmanDM, JagustW, JessenF, KarlawishJ, LiuE, MolinuevoJL, MontineT, PhelpsC, RankinKP, RoweCC, ScheltensP, SiemersE, SnyderHM, SperlingR (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement14, 535.
12.
LeuzyA, AshtonNJ, Mattsson-CarlgrenN, DodichA, BoccardiM, CorreJ, DrzezgaA, NordbergA, OssenkoppeleR, ZetterbergH, BlennowK, FrisoniGB, GaribottoV, HanssonO (2021) 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging48, 2121–2139.
13.
BaldeirasI, SantanaI, LeitãoMJ, GensH, PascoalR, Tábuas-PereiraM, Beato-CoelhoJ, DuroD, AlmeidaMR, OliveiraCR (2018) Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment. Alzheimers Res Ther10, 33.
14.
McCollumLE, DasSR, XieL, de FloresR, WangJ, XieSX, WisseLEM, YushkevichPA, WolkDA (2021) Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau. Neuroimage Clin31, 102717.
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5®), American Psychiatric Pub.
17.
NasreddineZS, PhillipsNA, BédirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH (2005) The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc53, 695–699.
18.
FasnachtJS, WueestAS, BerresM, ThomannAE, KrummS, GutbrodK, SteinerLA, GoettelN, MonschAU (2023) Conversion between the Montreal Cognitive Assessment and the Mini-Mental Status Examination. J Am Geriatr Soc71, 869–879.
19.
Van der LindenM, CoyetteF, PoitrenaudJ (2004) L’épreuve de rappel libre/rappel indicé à 16 items (RL/RI-16). Lévaluation Troubl Mém, pp. 25–47.
20.
HenryJD, CrawfordJR, PhillipsLH (2004) Verbal fluency performance in dementia of the Alzheimer’s type: A meta-analysis. Neuropsychologia42, 1212–1222.
21.
KesselsRPC, OverbeekA, BoumanZ (2015) Assessment of verbal and visuospatial working memory in mild cognitive impairment and Alzheimer’s dementia. Dement Neuropsychol9, 301–305.
TombaughTN (2004) Trail Making Test A and B: Normative data stratified by age and education. Arch Clin Neuropsychol19, 203–214.
24.
Sánchez-CubilloI, PeriáñezJA, Adrover-RoigD, Rodríguez-SánchezJM, Ríos-LagoM, TirapuJ, BarcelóF (2009) Construct validity of the Trail Making Test: Role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc15, 438–450.
25.
RaouxN, Le GoffM, AuriacombeS, DartiguesJ-F, AmievaH (2010) [Semantic and letter fluency tasks: Normative data in an elderly population of 70 years old and over from the PAQUID cohort]. Rev Neurol (Paris)166, 594–605.
26.
StroopJR (1935) Studies of interference in serial verbal reactions. J Exp Psychol18, 643–662.
27.
BayardS, ErkesJ, MoroniC, Collège des Psychologues Cliniciens spécialisés en Neuropsychologie du Languedoc Roussillon (CPCN Languedoc Roussillon) (2011) Victoria Stroop Test: Normative data in a sample group of older people and the study of their clinical applications in the assessment of inhibition in Alzheimer’s disease. Arch Clin Neuropsychol26, 653–661.
28.
Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study documents.
29.
SchmitterD, RocheA, MaréchalB, RibesD, AbdulkadirA, Bach-CuadraM, DaducciA, GranzieraC, KlöppelS, MaederP, MeuliR, KruegerG (2015) An evaluation of volume-based morphometry for prediction of mild cognitive impairment and Alzheimer’s disease. Neuroimage Clin7, 7–17.
30.
RocheA, MaréchalB, KoberT, HenryH, GuntenA von, MeuliR, PoppJ (2017) A volume-based automated morphometry tool for the prediction of cognitive decline and Alzheimer’s disease pathology in older subjects. J Neurol Sci381, 772.
BrenowitzWD, MonsellSE, SchmittFA, KukullWA, NelsonPT (2014) Hippocampal sclerosis of aging is a key Alzheimer’s disease mimic: Clinical-pathologic correlations and comparisons with both Alzheimer’s disease and non-tauopathic frontotemporal lobar degeneration. J Alzheimers Dis39, 691–702.
38.
MacchitellaL, TosiG, GiaquintoF, IaiaM, RizziE, ChiarelloY, BertouxM, AngelelliP, RomanoDL (2023) Genuine memory deficits as assessed by the Free and Cued Selective Reminding Test (FCSRT) in the behavioural variant of frontotemporal dementia. A systematic review and meta-analysis study. Neuropsychol Rev, doi: 10.1007/s11065-023-09613-3.
39.
JosephsKA, MurrayME, TosakulwongN, WhitwellJL, KnopmanDS, MachuldaMM, WeigandSD, BoeveBF, KantarciK, PetrucelliL, LoweVJ, JackCR, PetersenRC, ParisiJE, DicksonDW (2017) Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: A clinico-imaging-pathological study of primary age related tauopathy (PART). Acta Neuropathol (Berl)133, 705–715.
40.
ColeJ, CostafredaSG, McGuffinP, FuCHY (2011) Hippocampal atrophy in first episode depression: A meta-analysis of magnetic resonance imaging studies. J Affect Disord134, 483–487.
41.
Bastos-LeiteAJ, van der FlierWM, van StraatenECW, StaekenborgSS, ScheltensP, BarkhofF (2007) The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. Stroke38, 3182–3185.
42.
BesserLM, MockC, TeylanMA, HassenstabJ, KukullWA, CraryJF (2019) Differences in cognitive impairment in primary age-related tauopathy versus Alzheimer disease. J Neuropathol Exp Neurol78, 219–228.
43.
NelsonPT, SchneiderJA, JichaGA, DuongMT, WolkDA (2023) When Alzheimer’s is LATE: Why does it matter?Ann Neurol94, 211–222.
44.
Butler PagnottiRM, PudumjeeSB, CrossCL, MillerJB (2023) Cognitive and clinical characteristics of patients with limbic-predominant age-related TDP-43 encephalopathy. Neurology100, e2027–e2035.
45.
ReedBR, MungasDM, KramerJH, EllisW, VintersHV, ZarowC, JagustWJ, ChuiHC (2007) Profiles of neuropsychological impairment in autopsy-defined Alzheimer’s disease and cerebrovascular disease. Brain130, 731–739.
46.
SarazinM, ChauviréV, GerardinE, ColliotO, KinkingnéhunS, de SouzaLC, Hugonot-DienerL, GarneroL, LehéricyS, ChupinM, DuboisB (2010) The amnestic syndrome of hippocampal type in Alzheimer’s disease: An MRI study. J Alzheimers Dis22, 285–294.
47.
ChenX, TouegTN, HarrisonTM, BakerSL, JagustWJ (2024) Regional tau deposition reflects different pathways of subsequent neurodegeneration and memory decline in cognitively normal older adults. Ann Neurol95, 249–259.
48.
GuptaY, LeeKH, ChoiKY, LeeJJ, KimBC, KwonGR, Dementia the NRC for, Initiative ADN (2019) Early diagnosis of Alzheimer’s disease using combined features from voxel-based morphometry and cortical, subcortical, and hippocampus regions of MRI T1 brain images. PLOS One14, e0222446.
49.
SnowdenJS (2023) Changing perspectives on frontotemporal dementia: A review. J Neuropsychol17, 211–234.
50.
HoganDB, FiestKM, RobertsJI, MaxwellCJ, DykemanJ, PringsheimT, SteevesT, SmithEE, PearsonD, JettéN (2016) The prevalence and incidence of dementia with Lewy bodies: A systematic review. Can J Neurol Sci43, S83–S95.
